Volume 7.16 | May 6

Prostate Cell News 7.16 May 6, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
To study the effect of EPI on AR transcriptional activity against overexpressed co-activators such as SRC1-3 and p300, luciferase reporter assays were performed using LNCaP cells. [Clin Cancer Res] Abstract
Cryopreservation Media for Stem Cells - Learn More!
PUBLICATIONS (Ranked by impact factor of the journal)

Bone Marrow Mesenchymal Stem Cells Participate in Prostate Carcinogenesis and Promote Growth of Prostate Cancer by Cell Fusion In Vivo
Scientists established GFP bone marrow transplanted TRAMP and MUN-induced prostate cancer models, in order to investigate the role of bone marrow derived cells in prostate cancer progression. [Oncotarget] Full Article

SUMOylation of TBL1 and TBLR1 Promotes Androgen-Independent Prostate Cancer Cell Growth
Researchers demonstrated that cytokine production is significantly elevated in androgen-independent PC-3 prostate cancer cells compared with androgen-dependent LNCaP prostate cancer cells. [Oncotarget] Full Article

Human Antigen R Is Positively Associated with Malignant Aggressiveness via Upregulation of Cell Proliferation, Migration, and Vascular Endothelial Growth Factors and Cyclooxygenase-2 in Prostate Cancer
The authors clarified the relationship between human antigen R expression and malignant aggressiveness, outcome, and expression of cancer-related molecules in prostate cancer. In vitro proliferation, colony formation, and migration assays were performed on LNCaP and PC-3 cells. [Transl Res] Abstract

Resveratrol Directly Targets DDX5 Resulting in Suppression of the mTORC1 Pathway in Prostate Cancer
Scientists identified 11 novel resveratrol-binding proteins, including the DEAD box helicase 5 (DDX5), using resveratrol-immobilized beads. Treatment with resveratrol induced degradation of DDX5 in prostate cancer cells. [Cell Death Dis] Full Article

Sensitization of Androgen Refractory Prostate Cancer Cells to Anti-Androgens through Re-Expression of Epigenetically Repressed Androgen Receptor – Synergistic Action of Quercetin and Curcumin
Some dietary phytocompounds like quercetin and curcumin with reported DNMT-inhibitory activity were tested for their ability to re-express the androgen receptor (AR) in AR-negative prostate cancer cell lines PC3 and DU145. [Mol Cell Endocrinol] Abstract

A Convenient and Effective Strategy for the Enrichment of Tumor-Initiating Cell Properties in Prostate Cancer Cells
For stem-like prostate cancer (PrCa) tumor-initiating cells enrichment, investigators induced cancer stem cell properties in PrCa cells by transducing three defined factors, followed by culture with conventional serum-containing medium. [Tumor Biol] Abstract

Lymphatic Endothelial Cells Actively Regulate Prostate Cancer Cell Invasion
The authors investigated the role of lymphatic endothelial cell–prostate cancer (PCa) cell interaction in the invasion and degradation of the extracellular matrix by two human PCa cell lines, PC-3 and DU-145, under normoxia and hypoxia, and determined the metabolic changes that occurred under these conditions. [NMR Biomed] Abstract

The NF-κB Subunit RelB Regulates the Migration and Invasion Abilities and the Radio-Sensitivity of Prostate Cancer Cells
Researchers investigated systemically the functional roles of RelB in prostate cancer and examined its significance as a therapeutic target. Targeting RelB using short hairpin RNA approach in androgen-independent DU145 prostate cancer cells interfered with various biological behaviors of cells. [Int J Oncol] Abstract

Jungermannenone A and B Induce ROS- and Cell Cycle-Dependent Apoptosis in Prostate Cancer Cells In Vitro
Researchers investigated the mechanisms underlying the anticancer action of jungermannenone A and B in PC3 human prostate cancer cells in vitro. [Acta Pharmacol Sin] Abstract

Hypoxia Inducible Factor-1α-Dependent Epithelial to Mesenchymal Transition under Hypoxic Conditions in Prostate Cancer Cells
Scientists demonstrated that hypoxia induces diverse molecular, phenotypic and functional changes in prostate cancer cells that are consistent with EMT. They also showed that a cell signal factor such as HIF-1α, which might be stabilized under hypoxic environment, is involved in EMT and cancer cell invasive potency. [Oncol Rep] Abstract


Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
The authors revealed genomic characteristics from cell-free DNA associated with clinical outcomes during enzalutamide treatment. [JAMA Oncol] Abstract

Learn More: Standardized Tools for Cancer Research
Progesterone Receptor in the Prostate: A Potential Suppressor for Benign Prostatic Hyperplasia and Prostate Cancer
Recent progress in the understanding of stromal progesterone receptor (PR) function suggests that this receptor may exert an inhibitory effect on benign prostatic hyperplasia, reactive stroma development, and prostate cancer (PCa) progression. These early findings of stromal PR warrant further investigations as this receptor could be a potential biomarker and therapeutic target in PCa management. [J Steroid Biochem Mol Biol] Abstract

A Comprehensive Review of the Role of Zinc in Normal Prostate Function and Metabolism; and Its Implications in Prostate Cancer
The authors highlight the specific functional and metabolic alterations that result from the accumulation of the high zinc levels, especially its effects on mitochondrial citrate metabolism and terminal oxidation. The implications of zinc in the development and progression of prostate cancer are described, which is the most consistent hallmark characteristic of prostate cancer. [Arch Biochem Biophys] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Genentech Highlights Personalized Medicines and Cancer Immunotherapies
Genentech announced new results from 19 approved and investigational medicines will be presented. More than 200 abstracts have been accepted across eight cancer types, including four “late breakers” and nearly 30 oral presentations. [Press release from Genentech, Inc. discussing research to be presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
Watch the webinar.
SU2C Supports “Innovation in Collaboration” with $1 Million for Five Teams through Philip A. Sharp Awards
Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-affiliated scientists. Each team, consisting of researchers from different SU2C-supported “Dream Teams” or research programs, will receive a grant of $200,000 to support new research projects stemming from previous advances in cancer research from the SU2C community. [Stand Up To Cancer] Press Release

Prostate Cancer Foundation Announces New Chief Operating Officer John H. Weston
John H. Weston has been appointed Chief Operating Officer and Executive Vice President of the Prostate Cancer Foundation effective immediately reporting to Jonathan W. Simons, MD, President and CEO. [Prostate Cancer Foundation] Press Release
Nine Years of Censorship
Canadian scientists are now allowed to speak out about their work — and the government policy that had restricted communications. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 4th Global Congress on Prostate Cancer
June 29-July 1, 2016
Vienna, Austria

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellow – Cancer Genomics (Henry Jackson Foundation)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Mechanisms of Castrate Resistance (University of Chicago)

Postdoctoral Research Fellow – Molecular Epidemiology of Cancer (Fred Hutchinson Cancer Research Center)

PhD Studentship – Cancer Metabolism (German Cancer Research Center)

Postdoctoral Fellow – Genetic Determinants of Cancer (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Epithelial Homeostasis and Carcinogenesis (Baylor College of Medicine)

Lead Scientist – Prostate Cancer (Memorial Sloan Kettering Cancer Center)

Postdoctoral Fellowship – Castration Resistant Prostate Cancer (University of Florida)

Research Group Leader – Stress Regulated Processes During Oncogenesis (INSERM)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us